Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Niagen Bioscience, Inc. (NAGE : NSDQ)

• Company Description    Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES. Number of Employees: 117

• Price / Volume Information    Yesterday's Closing Price: $3.66 Daily Weekly Monthly 20 Day Moving Average: 1,024,827 shares Shares Outstanding: 79.64 (millions) Market Capitalization: $291.50 (millions) Beta: 2.17 52 Week High: $14.69 52 Week Low: $3.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.62% -26.40% 12 Week -29.34% -34.68% Year To Date -42.45% -45.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10900 Wilshire Blvd. Suite 600 - Los Angeles,CA 90024 USA ph: 310-388-6706 fax: 949-419-0294 niagenir@icrinc.com http://www.niagenbioscience.com

• General Corporate Information    Officers Robert Fried - Chief Executive Officer and Director Frank Jaksch - Chairman of the Board and Director Ozan Pamir - Chief Financial Officer Steven Rubin - Director Wendy Yu - Director Peer Information Niagen Bioscience, Inc. (CORR.) Niagen Bioscience, Inc. (RSPI) Niagen Bioscience, Inc. (CGXP) Niagen Bioscience, Inc. (BGEN) Niagen Bioscience, Inc. (GTBP) Niagen Bioscience, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171077407 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/05/26 Share - Related Items Shares Outstanding: 79.64 Most Recent Split Date: 4.00 (0.33:1) Beta: 2.17 Market Capitalization: $291.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.22 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/26

• Fundamental Ratios P/E Current FY Estimate: 16.89 Trailing 12 Months: 19.26 PEG Ratio: - Price Ratios Price/Book: 3.54 Price/Cash Flow: 18.05 Price / Sales: 2.24 EPS Growth vs. Year Ago Period: 75.00% vs. Previous Quarter: 133.33% Sales Growth vs. Year Ago Period: 3.26% vs. Previous Quarter: -6.99% ROE 03/31/26 - 22.68 12/31/25 - 21.10 09/30/25 - 24.13 ROA 03/31/26 - 16.23 12/31/25 - 14.92 09/30/25 - 16.81 Current Ratio 03/31/26 - 4.61 12/31/25 - 4.86 09/30/25 - 4.12 Quick Ratio 03/31/26 - 3.55 12/31/25 - 3.83 09/30/25 - 3.29 Operating Margin 03/31/26 - 12.77 12/31/25 - 10.87 09/30/25 - 11.43 Net Margin 03/31/26 - 14.29 12/31/25 - 13.43 09/30/25 - 16.38 Pre-Tax Margin 03/31/26 - 15.10 12/31/25 - 14.06 09/30/25 - 17.04 Book Value 03/31/26 - 1.03 12/31/25 - 0.96 09/30/25 - 0.89 Inventory Turnover 03/31/26 - 2.40 12/31/25 - 2.85 09/30/25 - 3.36 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©